Raymond James Upgrades PAREXEL International Corp. to Strong-Buy (PRXL)
PAREXEL International Corp. (NASDAQ: PRXL) was upgraded by equities research analysts at Raymond James from a “market perform” rating to a “strong-buy” rating in a research note issued to investors on Monday, TheFlyOnTheWall.com reports.
Several other analysts have also recently commented on the stock. Analysts at Zacks downgraded shares of PAREXEL International Corp. from an “outperform” rating to a “neutral” rating in a research note to investors on Thursday. They now have a $51.00 price target on the stock. Separately, analysts at Jefferies Group reiterated a “hold” rating on shares of PAREXEL International Corp. in a research note to investors on Thursday. They now have a $43.00 price target on the stock, up previously from $41.00. Finally, analysts at Sterne Agee initiated coverage on shares of PAREXEL International Corp. in a research note to investors on Tuesday, June 11th. They set a “neutral” rating and a $44.00 price target on the stock.
Six equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $43.71.
PAREXEL International Corp. (NASDAQ: PRXL) traded up 1.82% on Monday, hitting $46.805. PAREXEL International Corp. has a 52-week low of $23.75 and a 52-week high of $41.18. The stock’s 50-day moving average is currently $38.83. The company has a market cap of $2.661 billion and a price-to-earnings ratio of 32.86.
PAREXEL International Corp. (NASDAQ: PRXL) last announced its earnings results on Tuesday, April 30th. The company reported $0.50 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.40 by $0.10. The company had revenue of $454.49 million for the quarter, compared to the consensus estimate of $438.10 million. During the same quarter last year, the company posted $0.33 earnings per share. PAREXEL International Corp.’s revenue was up 27.7% compared to the same quarter last year. PAREXEL International Corp. has set its Q4 guidance at $0.40-0.44 EPS. Analysts expect that PAREXEL International Corp. will post $1.64 EPS for the current fiscal year.
PAREXEL International Corporation (NASDAQ: PRXL) is a biopharmaceutical services company, providing a range of expertise in clinical research, medical communications, consulting, and advanced technology products and services to the worldwide pharmaceutical, biotechnology, and medical device industries.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.